MENU ▼
Read by QxMD icon Read
search
OPEN IN READ APP
JOURNAL ARTICLE

Cardiovascular safety of linagliptin compared to other oral glucose lowering agents in patients with type 2 diabetes: a sequential monitoring program in routine care

E Patorno, C Gopalakrishnan, K G Brodovicz, A Meyers, D B Bartels, J Liu, M Kulldorff, S Schneeweiss
Diabetes, Obesity & Metabolism 2019 April 2
30941884

BACKGROUND: There are limited real-world data on the comparative cardiovascular (CV) safety of linagliptin, a dipeptidyl peptidase-4 inhibitor (DPP-4i) available since May 2011.

OBJECTIVES: We aimed to evaluate the safety of linagliptin vs. other glucose-lowering medications in a multi-year monitoring program using insurance claims data.

METHODS: In two commercial U.S. claims databases, we identified three pairwise 1:1 propensity score (PS) matched cohorts of type 2 diabetes (T2D) patients ≥18 years initiating linagliptin or a comparator [other DPP-4i (n=31,492 pairs), pioglitazone (n=23,316 pairs), or 2nd generation sulfonylureas (n=19,731 pairs)] between May 2011 and December 2015. The primary endpoint was the risk of a composite CV outcome (hospitalization for myocardial infarction, stroke, unstable angina, or coronary revascularization). We estimated pooled hazard ratios (HR) and 95% confidence intervals (CI) controlling for >100 baseline characteristics.

RESULTS: Patient characteristics were well balanced after PS-matching. Mean age was 55 years and mean follow-up was 0.8 years. Linagliptin had a similar risk of the composite CV outcome compared to other DPP-4is (HR = 0.91; 95% CI = 0.79-1.05) and pioglitazone (0.98; 0.84-1.15), and showed a reduced risk of CV outcomes compared to 2nd generation sulfonylureas (0.76; 0.64-0.92). Key findings signaled at the first interim analysis in June 2013 and solidified during ongoing monitoring through 2015.

CONCLUSION: Analyses from a large monitoring program in routine care of patients with T2D, showed that linagliptin had similar cardiovascular safety compared to other DPP-4i and pioglitazone, and a reduced cardiovascular risk compared to sulfonylureas. This article is protected by copyright. All rights reserved.

Comments

You need to log in or sign up for an account to be able to comment.

No comments yet, be the first to post one!

Trending on Read

Available on the App Store

Available on the Play Store
Remove bar
Read by QxMD icon Read
30941884
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"